Edward P. Scott, MD will participate in a new clinical trial by Dendreon, maker of Provenge, the first FDA-approved (2010) autologous cell immunotherapy for tumors. According to a news release, the breakthrough sipuleucel-T treatment targets metastatic, hormone-refractory prostate cancer to improve survivability - and has encouraged other solid-tumor immuno-oncology researchers.
The new 'ProVent' study will evaluate the drug's efficacy in reducing or halting disease progression and/or delaying definitive therapies in 300 subjects against the disease progression and quality-of-life in 150 Active Surveillance subjects. Johns Hopkins' research shows 30-40 percent of early-stage prostrate patients opt to delay or forego treatment to avoid often life-altering effects of radiation and surgery1. The study will begin enrolling inclusive, early-stage and late-stage patients for the 18 month investigative course later this fall.
A research affiliate since Dendreon's original 2005 sipuleucil-T trial, Scott continues working with 70 patients annually referred by Mid-South oncologists for non-study Provenge cell-based therapy. Urologist Paul R. Eber, MD of The Conrad Pearson Clinic, also a long-experienced Provenge therapy facilitator will serve as a clinical trial investigative site clinician for the ProVent study.
Scott and his Key Biologics medical team will conduct critical leukaphareses and proprietary cell processing of study patients enrolled in the targeted treatment group. Specialized WBC collections provide the antigen-presenting dendritic cells and T cells to Dendreon that are lab-incubated with a fusion protein to target prostate cancer cells, stimulated to mature, and returned to the patient by infusion. Each patient will undergo three tailored aphereses under the hematologist's care.